Komori
Seikagaku (4548) · RiskRestated

Risk of Changes in Pharmaceutical Regulations in Japan and Overseas

First written in FY2016. 2 of 3 entries say "Restated". Latest entry: FY2021.

3entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20212016: 120162017: 120172018: 020182019: 020192020: 020202021: 12021
Same theme, other companies
Market and earnings impact on the pharmaceutical business from drug price revisions, healthcare system changes and pricing policy changesA theme 88 companies write about · 104 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2018: 19 of 64 companies on the "Worse" side.

47 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 88 companies compared. The sentences above are computed from all 88.
Full recordFilings, disclosures and news, newest first
  1. FY2021RestatedAnnual report

    「Depending on developments in healthcare systems and government policies, including amendments to these related laws and regulations and revisions to official drug prices, the company's performance may be materially affected.」

    The disclosure continues to identify the risk that, in addition to regulatory and legal changes in Japan and overseas, revisions to official drug prices and developments in healthcare systems and government policies may affect the company's performance.
  2. FY2017RestatedAnnual report

    「Depending on developments at regulatory authorities, including amendments to these related laws and regulations, the company's performance may be affected.」

    The disclosure reiterates that amendments to pharmaceutical regulations and related laws and regulations in Japan and overseas may affect the company's performance.
  3. FY2016First statedAnnual report

    「The company is subject to legal regulations imposed by regulatory authorities in Japan and other countries to ensure the quality, efficacy and safety of pharmaceuticals and other products. Depending on developments at regulatory authorities, including amendments to these related laws and regulations, the company's performance may be affected.」

    This indicates that developments at regulatory authorities and amendments to related laws and regulations may affect the company's performance.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Seikagaku yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Changes in Pharmaceutical Regulations in Japan and Overseas | SEIKAGAKU CORPORATION (4548) | Komori